N-<2-(diethylamino)ethyl>-2',6'-xylidine | 21236-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<2-(diethylamino)ethyl>-2',6'-xylidine
• 英文别名: N,N-diethyl-N'-(2,6-dimethylphenyl)-1,2-ethanediamine；N,N-diethyl-N'-(2,6-dimethyl-phenyl)-ethylenediamine；N,N-Diaethyl-N'-(2,6-dimethyl-phenyl)-aethylendiamin；N-(2,6-dimethylphenyl)-N',N'-diethylethane-1,2-diamine
• CAS: 21236-57-7
• 化学式: C₁₄H₂₄N₂
• 分子量: 220.358
• InChiKey: YHHHQLCTJCJHKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  152-153 °C(Press: 9 Torr)
• 密度：
  0.952±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-<2-(diethylamino)ethyl>-2',6'-xylidine 、 氯甲酸乙酯 生成 (2-diethylamino-ethyl)-(2,6-dimethyl-phenyl)-carbamic acid ethyl ester
  参考文献：
  名称：

  Larizza; Pellegrino, Gazzetta Chimica Italiana, 1959, vol. 89, p. 2018,2020

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二乙基氯乙胺 、 2,6-二甲基苯胺 以 乙醇 为溶剂， 反应 0.5h， 以40%的产率得到N-<2-(diethylamino)ethyl>-2',6'-xylidine
  参考文献：
  名称：

  新型抗心律失常药。5.具有官能化的酰胺烷基取代基的α-氨基乙酰基2，6-二甲苯基。

  摘要：

  描述了在酰胺氮上被2-（二乙基氨基）乙基，2-氨基乙基，2-羟基乙基和2-乙氧基乙基取代的氨基乙酰基2′，6′-二甲苯基的合成。通过用氯乙酰氯处理N-（2-邻苯二甲酰亚胺基乙基）-2'，6'-二甲基吡啶，然后用邻苯二甲酰亚胺钾或二乙胺处理来制备2-氨基乙基衍生物。邻苯二甲酰亚胺的肼解作用释放出游离胺。剩余的目标化合物是通过利多卡因或2-phthalimidoaceto-2'，6'-二甲苯基与适当的卤化物和氢化钠烷基化，然后在必要时进行肼解反应制得的。评估了所有目标化合物对氯仿诱导的室性心动过速的抗心律失常功效，以及对小鼠的急性中枢神经系统毒性。大多数目标化合物比相应的仲酰胺更有效，并且对中枢神经系统毒性具有更好的治疗效果。二胺N-（2-氨基乙基）-2-氨基乙酰基2'，6'-木糖苷（13）和N-（2-氨基乙基）-2-（二乙基氨基）乙酰基-2'，6'-木糖苷（29 ）在这方面特别有前途。测试了几种化合物作为脊髓麻醉剂。

  DOI：

  10.1021/jm00133a012

文献信息

• N-(aminoalkyl)-substituted(N or C
  申请人：Schering A.G.

  公开号：US04920116A1

  公开（公告）日：1990-04-24

  N-(aminoalkyl)-substituted(N or C alkyl)-aryl-4-(methylsylfonylamino)benzamides of the formula ##STR1## wherein R is C.sub.1 -C.sub.4 straight chain alkyl, one of R.sub.1, R.sub.2 and R.sub.3 is a phenyl or naphthyl group and the others are hydrogen, --NR.sub.4 R.sub.5 is a secondary or teritary amino group, X and X.sub.1 are hydrogen or alkyl and n is 0 or 1, are useful as antiarrhythmic agents in the treatment of cardiac arrhythmias especially as combination Class I/Class III agents.

  公式为##STR1##的N-(氨基烷基)-取代(N或C烷基)-芳基-4-(甲基磺酰氨基)苯甲酰胺，其中R为C.sub.1-C.sub.4直链烷基，R.sub.1、R.sub.2和R.sub.3中的一个为苯基或萘基，其余为氢，--NR.sub.4 R.sub.5为二级或三级氨基基团，X和X.sub.1为氢或烷基，n为0或1，可用于治疗心律失常，特别是作为I类/III类联合药物。
• Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents
  作者：Gary B. Phillips、Thomas K. Morgan、Klaus Nickisch、Joan M. Lind、Robert P. Gomez、Ronald A. Wohl、Thomas M. Argentieri、Mark E. Sullivan

  DOI：10.1021/jm00164a025

  日期：1990.2

  Twelve novel derivatives of the selective class III antiarrhythmic agent sematilide were prepared in an attempt to incorporate both class I and class III electrophysiological properties into a single molecule. Electrophysiological activity was determined by standard microelectrode techniques in canine cardiac Purkinje fibers. Initial assessment of class I efficacy was carried out in a ouabain-induced arrhythmia model in guinea pigs. All of the compounds prolonged action potential duration in Purkinje fibers (class III activity), and three were active against ouabain-induced arrhythmias (class I activity). Selected compounds were evaluated further in dogs for efficacy against arrhythmias occurring 24 h following coronary ligation (automatic arrhythmias) and induced by using programmed electrical stimulation techniques (reentrant arrhythmias). The most effective compounds from the series are 3g and -j, which were effective in both canine models. Molecular modeling and structure-activity relationships are discussed.
• SANDBERG R.; SALAZAR C. R.; SJVEBERG B.; AKERMAN B., ACTA PHARM. SUEC., 1980, 17, NO 4, 183-188
  作者：SANDBERG R.、 SALAZAR C. R.、 SJVEBERG B.、 AKERMAN B.

  DOI：——

  日期：——
• MCMASTER P. D.; BYRNES E. W.; BLOCK A. J.; TENTHOREY P. A., J. MED. CHEM., 1981, 24, NO 1, 53-58
  作者：MCMASTER P. D.、 BYRNES E. W.、 BLOCK A. J.、 TENTHOREY P. A.

  DOI：——

  日期：——
• ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0324791A1

  公开（公告）日：1989-07-26